Presentation is loading. Please wait.

Presentation is loading. Please wait.

Jordan B. King et al. JCHF 2016;4:

Published byNatividad Escobar Modified over 5 years ago

Similar presentations

Presentation on theme: "Jordan B. King et al. JCHF 2016;4:"— Presentation transcript:

1 Jordan B. King et al. JCHF 2016;4:392-402
ScatterPlot of Incremental Costs and Incremental QALYs Over a Lifetime for Sacubitril-Valsartan Relative to Enalapril Probabilistic sensitivity analysis results of 10,000 model simulations. Results reflect the effect of uncertainty in the model on differences in costs and quality-adjusted life-years (QALYs) for patients taking sacubitril-valsartan relative to those taking enalapril. Jordan B. King et al. JCHF 2016;4: American College of Cardiology Foundation

Download ppt "Jordan B. King et al. JCHF 2016;4:"

Similar presentations

This presentation reflects the views of the presenter and does not necessarily reflect the views of the American College of Cardiology Content Distributed.

This presentation reflects the views of the presenter and does not necessarily reflect the views of the American College of Cardiology Content Distributed.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Time to Cost-Effectiveness Following Stroke Reduction.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Time to Cost-Effectiveness Following Stroke Reduction.
From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.

From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
Volume 18, Issue 2, Pages (March 2015)

Volume 18, Issue 2, Pages (March 2015)
Markov model structure

Markov model structure
Pablo Ávila et al. JACEP 2015;1:

Pablo Ávila et al. JACEP 2015;1:
Dean J. Kereiakes et al. JACC 2017;70:

Dean J. Kereiakes et al. JACC 2017;70:
Orly Vardeny et al. JCHF 2014;2:

Orly Vardeny et al. JCHF 2014;2:
G. Michael Felker et al. JCHF 2014;2:

G. Michael Felker et al. JCHF 2014;2:
Kenshi Hayashi et al. JACEP 2016;2:

Kenshi Hayashi et al. JACEP 2016;2:
Carolyn Y. Ho et al. JCHF 2015;3:

Carolyn Y. Ho et al. JCHF 2015;3:
Caroline Zotter-Tufaro et al. JCHF 2015;3:

Caroline Zotter-Tufaro et al. JCHF 2015;3:
Belinda Gray et al. JCHF 2013;1:

Belinda Gray et al. JCHF 2013;1:
Pablo B. Nery et al. JACEP 2016;2:

Pablo B. Nery et al. JACEP 2016;2:
Patrick M. Boyle et al. JACEP 2018;4:

Patrick M. Boyle et al. JACEP 2018;4:
Wayne L. Miller et al. JCHF 2013;1:

Wayne L. Miller et al. JCHF 2013;1:
Prakash Harikrishnan et al. JACEP 2015;1:

Prakash Harikrishnan et al. JACEP 2015;1:
G. Michael Felker et al. JCHF 2014;2:

G. Michael Felker et al. JCHF 2014;2:
Svend A. Mortensen et al. JCHF 2014;2:

Svend A. Mortensen et al. JCHF 2014;2:
Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368: 679-86.

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Similar presentations

Ads by Google